{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"0.4","value":"0.3"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"13.9","value":"4.1"},{"comment":"Confidence interval could not be calculated as only one participant was analyzed","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"2.2"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"13.9","value":"9.1"},{"groupId":"OG004","lowerLimit":"0.9","upperLimit":"5.4","value":"3.8"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"8.9","value":"3.6"},{"groupId":"OG006","lowerLimit":"2.6","upperLimit":"9.1","value":"6.5"},{"groupId":"OG007","lowerLimit":"6.0","upperLimit":"18.0","value":"7.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.38 months of drug exposure","title":"Progression Free Survival-Part 1 QD","type":"SECONDARY","unitOfMeasure":"Months"}